Are National Drug Expenditure Control Policies Compatible with a Single European Market? Joan Rovira OriginalPaper 15 November 2012 Pages: 4 - 13
Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany Oliver Schöffski OriginalPaper 15 November 2012 Pages: 37 - 47
An Introduction to Three Studies Assessing the Impact of Specific Restraints on the Delivery of Pharmaceutical Benefits Alvin R. Tarlov Discussion Paper 15 November 2012 Pages: 48 - 49
The Clinical Practice Improvement (CPI) Model and How it Is Used to Examine the Availability of Pharmaceuticals and the Utilisation of Ambulatory Healthcare Services in HMOs Susan D. Horn OriginalPaper 15 November 2012 Pages: 50 - 55
A Framework for Cost-Sharing Policy Analysis Robert J. RubinDaniel N. Mendelson OriginalPaper 15 November 2012 Pages: 56 - 67
Cost Sharing for Pharmaceuticals — The Swedish Reimbursement System Beugt Jönsson OriginalPaper 15 November 2012 Pages: 68 - 74
The 1996 Pricing and Reimbursement Policy in The Netherlands Cornelis M. de Vos OriginalPaper 15 November 2012 Pages: 75 - 80
Healthcare Reform and Expenditure on Drugs Volker UlrichEberhard Wille OriginalPaper 15 November 2012 Pages: 81 - 88
Culture and Politics in Healthcare Reform Kevin C. Vigilante OriginalPaper 15 November 2012 Pages: 89 - 93
Longer Patents for Increased Generic Competition in the US Henry GrabowskiJohn Vernon OriginalPaper 15 November 2012 Pages: 110 - 123
Drug Use in Academic Medical Centres in an Era of Ferment Jerry Avorn OriginalPaper 15 November 2012 Pages: 124 - 129
Towards a Research Agenda for Pharmaceutical Issues Paul R. Meyer OriginalPaper 15 November 2012 Pages: 130 - 134
A Research Agenda for Pharmaceutical Issues Robert B. Helms Discussion Paper 15 November 2012 Pages: 135 - 138
